Filtered By:
Therapy: Corticosteroid Therapy
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 21 results found since Jan 2013.
Highlights into historical and current immune interventions for cancer
Int Immunopharmacol. 2023 Feb 27;117:109882. doi: 10.1016/j.intimp.2023.109882. Online ahead of print.ABSTRACTImmunotherapy is an additional pillar when combined with traditional standards of care such as chemotherapy, radiotherapy, and surgery for cancer patients. It has revolutionized cancer treatment and rejuvenated the field of tumor immunology. Several types of immunotherapies, including adoptive cellular therapy (ACT) and checkpoint inhibitors (CPIs), can induce durable clinical responses. However, their efficacies vary, and only subsets of cancer patients benefit from their use. In this review, we address three goal...
Source: International Immunopharmacology - February 27, 2023 Category: Allergy & Immunology Authors: Kathryn Cole Zaid Al-Kadhimi James E Talmadge Source Type: research
End of year message from Cochrane ' s CEO, Catherine Spencer
Dear Cochrane Colleagues, Members and Supporters, Thank you to everyone across our community for your dedication and commitment to Cochrane during 2022. The last few years have at times felt tumultuous, both due to Covid and world events, but also because of the changes we are making to ensure that Cochrane is fit for a future that meets our vision of aworld of better health for all people, where decisions about health and care are informed by high-quality evidence. We are well on our way to creating an evolved impact-driven organisation to support evidence-based health and social care. With your help we are building on ...
Source: Cochrane News and Events - December 20, 2022 Category: Information Technology Authors: Muriah Umoquit Source Type: news
The Effect of Dexamethasone Treatment on COVID-19 Prognosis in Cancer Patients
CONCLUSION: Our data showed that dexamethasone therapy protocol affected COVID-19 prognoses in cancer patients, and it is preferable to not discontinue therapy after infection. A rigorous prospective comparison between early and late dexamethasone dosing is needed to determine the best protocol for treatment.PMID:36366306 | DOI:10.3390/vaccines10111798
Source: Cancer Control - November 11, 2022 Category: Cancer & Oncology Authors: Lina Souan Zienab Al-Khairy Maysaa' Adnan Al-Binni Abdelkader Battah Maher A Sughayer Source Type: research
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
Thrombosis, cancer, and COVID-19
Support Care Cancer. 2022 May 14. doi: 10.1007/s00520-022-07098-z. Online ahead of print.ABSTRACTCancer and coronavirus disease 2019 (COVID-19) have unusual similarities: they both result in a markedly elevated risk of thrombosis, exceptionally high D-dimer levels, and the failure of anticoagulation therapy in some cases. Cancer patients are more vulnerable to COVID-19 infection and have a higher mortality rate. Science has uncovered much about SARS-CoV-2, and made extraordinary and unprecedented progress on the development of various treatment strategies and COVID-19 vaccines. In this review, we discuss known data on canc...
Source: Cancer Control - May 14, 2022 Category: Cancer & Oncology Authors: Norman Brito-Dellan Nikolaos Tsoukalas Carme Font Source Type: research
Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study
CONCLUSIONS: These findings suggest that simple and widely available peripheral counts of T helper and B cells correlate with humoral response to mRNA-BNT162b2 vaccine in actively treated cancer patients. Upon validation, our results could provide additional insights into the predictive assessment of vaccination efficacy.PMID:35461110 | DOI:10.1016/j.intimp.2022.108774
Source: International Immunopharmacology - April 23, 2022 Category: Allergy & Immunology Authors: Fabrizio Nelli Agnese Fabbri Valentina Panichi Diana Giannarelli Giuseppe Topini Julio R Giron Berrios Antonella Virtuoso Eleonora Marrucci Marco Mazzotta Marta Schirripa Carlo Signorelli Mario G Chilelli Francesca Primi Maria A Silvestri Enzo M Ruggeri Source Type: research
Roche COVID-19 At-Home Test granted FDA Emergency Use Authorization to expand access to rapid self-testing solutions in the United States
Rapid test to support the American public ’s fight against the COVID-19 pandemic, with availability to purchase over-the-counter (OTC) at pharmacies and retailers nationwideThe COVID-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron.EUA granted through Roche ’s participation in the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Independent Test Assessment Program to bring rapid tests to the OTC marketBasel, 24 ...
Source: Roche Media News - December 24, 2021 Category: Pharmaceuticals Source Type: news
Corticosteroid Use in Otolaryngology: Current Considerations During the COVID-19 Era
CONCLUSIONS: Systemic corticosteroids (SCSs) reduce long-term morbidity in individuals with SSNHL and Bell's palsy, reduce acute laryngotracheal edema, and have benefit in perioperative management for some procedures. Topical or locally injected corticosteroids are preferable for most other otolaryngologic indications. SCSs have not shown long-term benefit for sinonasal disorders. SCSs are not a contraindication to vaccination with COVID-19 vaccines approved by the US Food and Drug Administration. The Centers for Disease Control and Prevention noted that these vaccines are safe for immunocompromised patients.IMPLICATIONS F...
Source: Cancer Control - December 7, 2021 Category: Cancer & Oncology Authors: C W David Chang Edward D McCoul Selena E Briggs Elizabeth A Guardiani Marlene L Durand Tessa A Hadlock Alexander T Hillel Nrusheel Kattar Peter J M Openshaw Nosayaba Osazuwa-Peters David M Poetker Jennifer J Shin Sujana S Chandrasekhar Carol R Bradford Mi Source Type: research
Impact of the use of systemic corticosteroid therapy on the effectiveness of immune checkpoint inhibitors
Bull Cancer. 2021 Apr 19:S0007-4551(21)00121-1. doi: 10.1016/j.bulcan.2021.01.015. Online ahead of print.ABSTRACTImmunotherapy, which consists in using molecules targeting the immune system, has existed for many years in oncology (vaccines, interleukins, monoclonal antibodies) but has recently expanded due to the development of immune checkpoint inhibitors. These monoclonal antibodies help to restore the immunity against cancer by specifically targeting some immune checkpoints such as CTLA-4, PD-1 and PD-L1. Furthermore, in oncology, it is common to use systemic corticosteroids in the management of symptoms linked to the n...
Source: Bulletin du Cancer - April 23, 2021 Category: Cancer & Oncology Authors: Reda El Hazzaz Maria Kfoury Pernelle Lavaud Aur élien Marabelle St éphane Champiat Nawfel Mellas Benjamin Besse Christophe Massard Arthur Geraud Source Type: research
